Jupiter Neurosciences Adds Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board for Neurodegenerative Treatment Development

Jupiter Neurosciences has announced the appointment of Kristopher Fishman and Sanjiv Lal to its Nugevia Advisory Board. The company, which focuses on developing treatments for neurodegenerative diseases, confirmed the addition of these two professionals as part of its efforts to enhance strategic guidance for its flagship product, Nugevia.

Kristopher Fishman brings extensive experience in pharmaceutical development and commercialization, while Sanjiv Lal offers a background in clinical research and regulatory affairs. Their combined expertise is expected to contribute to the advancement of Nugevia, a treatment under development aimed at addressing neurological conditions. Jupiter Neurosciences stated that this move aligns with its broader strategy to strengthen its advisory capabilities as it progresses through key stages of product development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI